Author:
Braicu Cornelia,Bica Cecilia,Pop Laura-Ancuta,Zanoaga Oana,Chiroi Paul Adrian,Ciocan Cristina Alexandra,Nutu Andreea,Berindan-Neagoe Ioana
Publisher
Springer International Publishing
Reference115 articles.
1. Abrantes R, Duarte HO, Gomes C, Wälchli S, Reis CA (2022) CAR-Ts: new perspectives in cancer therapy. FEBS Lett 596:403–416
2. Akinleye A, Rasool Z (2019) Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol 12(1):92
3. Amaria RN, Reuben A, Cooper ZA, Wargo JA (2015) Update on use of aldesleukin for treatment of high-risk metastatic melanoma. ImmunoTargets Ther 4:79–89
4. Anagnostou V, Bruhm DC, Niknafs N, White JR, Shao XM, Sidhom JW et al (2020) Integrative tumor and immune cell multi-omic analyses predict response to immune checkpoint blockade in melanoma. Cell Rep Med 1(8):100139
5. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372(4):311–319